1. Home
  2. CHEK vs ENSC Comparison

CHEK vs ENSC Comparison

Compare CHEK & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHEK
  • ENSC
  • Stock Information
  • Founded
  • CHEK 2004
  • ENSC 2003
  • Country
  • CHEK Israel
  • ENSC United States
  • Employees
  • CHEK N/A
  • ENSC N/A
  • Industry
  • CHEK Medical Electronics
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHEK Health Care
  • ENSC Health Care
  • Exchange
  • CHEK Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • CHEK 4.4M
  • ENSC 4.9M
  • IPO Year
  • CHEK 2015
  • ENSC N/A
  • Fundamental
  • Price
  • CHEK N/A
  • ENSC $2.28
  • Analyst Decision
  • CHEK
  • ENSC
  • Analyst Count
  • CHEK 0
  • ENSC 0
  • Target Price
  • CHEK N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • CHEK 28.3K
  • ENSC 64.8K
  • Earning Date
  • CHEK 08-14-2025
  • ENSC 08-13-2025
  • Dividend Yield
  • CHEK N/A
  • ENSC N/A
  • EPS Growth
  • CHEK N/A
  • ENSC N/A
  • EPS
  • CHEK N/A
  • ENSC N/A
  • Revenue
  • CHEK N/A
  • ENSC $6,224,081.00
  • Revenue This Year
  • CHEK N/A
  • ENSC N/A
  • Revenue Next Year
  • CHEK N/A
  • ENSC $1,381.48
  • P/E Ratio
  • CHEK N/A
  • ENSC N/A
  • Revenue Growth
  • CHEK N/A
  • ENSC 256.35
  • 52 Week Low
  • CHEK $0.56
  • ENSC $1.62
  • 52 Week High
  • CHEK $3.04
  • ENSC $14.67
  • Technical
  • Relative Strength Index (RSI)
  • CHEK 41.81
  • ENSC 53.77
  • Support Level
  • CHEK $0.75
  • ENSC $2.15
  • Resistance Level
  • CHEK $0.86
  • ENSC $2.34
  • Average True Range (ATR)
  • CHEK 0.03
  • ENSC 0.10
  • MACD
  • CHEK 0.00
  • ENSC 0.03
  • Stochastic Oscillator
  • CHEK 19.59
  • ENSC 90.63

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: